Last reviewed · How we verify
LABA+LAMA+ICS
LABA+LAMA+ICS is a Small molecule drug developed by University of British Columbia. It is currently FDA-approved. Also known as: Trelegy Ellipta.
QVM149, a small molecule combination of indacaterol acetate, glycopyrronium bromide, and mometasone furoate, is being studied for its efficacy and safety in treating asthma, chronic obstructive pulmonary disease (COPD), severe eosinophilic asthma, and other pulmonary diseases. QVM149 is being compared to salmeterol xinafoate/fluticasone propionate in clinical trials.
At a glance
| Generic name | LABA+LAMA+ICS |
|---|---|
| Also known as | Trelegy Ellipta |
| Sponsor | University of British Columbia |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation (PHASE4)
- Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PHASE3)
- Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)
- Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). (PHASE3)
- Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD
- A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils (PHASE2)
- Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LABA+LAMA+ICS CI brief — competitive landscape report
- LABA+LAMA+ICS updates RSS · CI watch RSS
- University of British Columbia portfolio CI
Frequently asked questions about LABA+LAMA+ICS
What is LABA+LAMA+ICS?
Who makes LABA+LAMA+ICS?
Is LABA+LAMA+ICS also known as anything else?
What development phase is LABA+LAMA+ICS in?
Related
- Manufacturer: University of British Columbia — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Trelegy Ellipta
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing